Generalized Myasthenia Gravis Gmg clinical trials

Explore recruiting generalized myasthenia gravis gmg clinical trials.

Recruiting generalized myasthenia gravis gmg studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Generalized Myasthenia Gravis Gmg trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A PHASE 2, RANDOMIZED, BLINDED, PLACEBOCONTROLLED, STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOMETRICS, AND EFFICACY OF DNTH103 IN ADULTS WITH GENERALIZED MYASTHENIA GRAVIS (MAGIC)

Denmark, Poland, France, Netherlands, Norway, Italy +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study with an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis

Italy, Belgium, France, Spain, Denmark, Poland +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open-label, multi-center, phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasthenia Gravis (gMG)

Romania, Germany, Italy, Poland, Spain, Hungary

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and Safety of Nipocalimab vs Efgartigimod in a Randomized, Open-label, Phase 3b, Interventional Trial Including Within Class Switching From Efgartigimod to Nipocalimab

Austria, Germany, Spain, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

OCTAGON:A Phase 4, Single Arm Study to Investigate Oral Corticosteroid Tapering in Adult Patients with Generalized Myasthenia Gravis Treated with Ravulizumab

Italy, Germany

Therapeutic use (Phase IV) EU CTIS Study details

Generalized Myasthenia Gravis Gmg trials by city

Generalized Myasthenia Gravis Gmg in Toronto Generalized Myasthenia Gravis Gmg in Vancouver Generalized Myasthenia Gravis Gmg in Montreal Generalized Myasthenia Gravis Gmg in Calgary Generalized Myasthenia Gravis Gmg in Edmonton Generalized Myasthenia Gravis Gmg in Ottawa Generalized Myasthenia Gravis Gmg in Winnipeg Generalized Myasthenia Gravis Gmg in Quebec City Generalized Myasthenia Gravis Gmg in Hamilton Generalized Myasthenia Gravis Gmg in Kitchener Generalized Myasthenia Gravis Gmg in London Generalized Myasthenia Gravis Gmg in Halifax Generalized Myasthenia Gravis Gmg in New York Generalized Myasthenia Gravis Gmg in Los Angeles Generalized Myasthenia Gravis Gmg in Chicago Generalized Myasthenia Gravis Gmg in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease